» Articles » PMID: 35062699

Allergy Associated Myocardial Infarction: A Comprehensive Report of Clinical Presentation, Diagnosis and Management of Kounis Syndrome

Overview
Date 2022 Jan 22
PMID 35062699
Authors
Affiliations
Soon will be listed here.
Abstract

Kounis syndrome (KS) has been defined as acute coronary syndrome (ACS) in the context of a hypersensitivity reaction. Patients may present with normal coronary arteries (Type I), established coronary artery disease (Type II) or in-stent thrombosis and restenosis (Type III). We searched PubMed until 1 January 2020 for KS case reports. Patients with age <18 years, non-coronary vascular manifestations or without an established diagnosis were excluded. Information regarding patient demographics, medical history, presentation, allergic reaction trigger, angiography, laboratory values and management were extracted from every report. The data were pulled in a combined dataset. From 288 patients with KS, 57.6% had Type I, 24.7% Type II and 6.6% Type III, while 11.1% could not be classified. The mean age was 54.1 years and 70.6% were male. Most presented with a combination of cardiac and allergic symptoms, with medication being the most common trigger. Electrocardiographically, 75.1% had ST segment elevation with only 3.3% demonstrating no abnormalities. Coronary imaging was available in 84.8% of the patients, showing occlusive lesions (32.5%), vascular spasm (16.2%) or normal coronary arteries (51.3%). Revascularization was pursued in 29.4% of the cases. In conclusion, allergic reactions may be complicated by ACS. KS should be considered in the differential diagnosis of myocardial infarction with non-obstructive coronary arteries.

Citing Articles

Resuscitation of a case of allergy, infarction, and ventricular fibrillation: Kounis syndrome type II and literature review.

Li Y, Yu Q, Zhang W, Shi B Am J Transl Res. 2025; 16(12):7868-7874.

PMID: 39822530 PMC: 11733315. DOI: 10.62347/SAQA3325.


Kounis syndrome following COVID-19 vaccination: Clinical manifestations, mechanisms and management.

Zhao C, Lei R, Liu S, Zhao M Hum Vaccin Immunother. 2024; 20(1):2365496.

PMID: 39693186 PMC: 11188795. DOI: 10.1080/21645515.2024.2365496.


Kounis Syndrome: Review of Clinical Cases.

Yakushin S, Gurbanova A, Pereverzeva K Cardiovasc Hematol Disord Drug Targets. 2024; 24(2):83-97.

PMID: 39021170 DOI: 10.2174/011871529X305833240708051508.


Kounis Syndrome After Administration of Ultrasound Enhancing Agent.

Yopes M, Larnard E, Liu S, Stout J, Matos J, Osborn E Circ Cardiovasc Imaging. 2024; 17(3):e016362.

PMID: 38415350 PMC: 10950526. DOI: 10.1161/CIRCIMAGING.123.016362.


Identification of the biological processes, immune cell landscape, and hub genes shared by acute anaphylaxis and ST-segment elevation myocardial infarction.

Peng Z, Chen H, Wang M Front Pharmacol. 2023; 14:1211332.

PMID: 37469874 PMC: 10353022. DOI: 10.3389/fphar.2023.1211332.


References
1.
Paratz E, Khav N, Burns A . Systemic Mastocytosis, Kounis Syndrome and Coronary Intervention: Case Report and Systematic Review. Heart Lung Circ. 2017; 26(8):772-778. DOI: 10.1016/j.hlc.2016.12.009. View

2.
Raggi P, Genest J, Giles J, Rayner K, Dwivedi G, Beanlands R . Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018; 276:98-108. DOI: 10.1016/j.atherosclerosis.2018.07.014. View

3.
Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

4.
Guedeney P, Claessen B, Kalkman D, Aquino M, Sorrentino S, Giustino G . Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019; 73(19):2401-2409. DOI: 10.1016/j.jacc.2019.01.077. View

5.
Mueller U . Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol. 2007; 7(4):337-41. DOI: 10.1097/ACI.0b013e328259c328. View